Trevi Therapeutics, Inc. TRVI Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.19M-58.6% | -$8.32M+29.5% | -$11.8M+4.1% | -$12.3M-19.0% | -$10.34M+9.4% | ||
| $34K+9.7% | $31K-18.4% | $38K0.0% | $38K+2.7% | $37K-2.6% | ||
| $2.19M+62.3% | $1.35M+8.6% | $1.24M-10.2% | $1.38M+14.6% | $1.21M+31.7% | ||
| -$1.48M— | —— | -$282K— | —— | -$1.99M-211% | ||
| -$1.08M-93.7% | -$555K— | —— | —— | -$1.5M— | ||
| $2.84M— | —— | $30K-97.0% | $1M+65.5% | $605K— | ||
| $105K-1.9% | $107K-0.9% | $108K-1.8% | $110K-1.8% | $112K-43.4% | ||
| -$16.69M-119% | -$7.63M+29.9% | -$10.88M-7.7% | -$10.1M+25.1% | -$13.48M-41.1% | ||
| $102K— | —— | $12K— | —— | —— | ||
| $25.55M+7.4% | $23.79M+15.0% | $20.68M+42.6% | $14.5M-17.6% | $17.6M-17.5% | ||
| $16.97M+155% | -$30.61M+39.9% | -$50.94M-1,852% | -$2.61M+73.8% | -$9.95M+58.3% | ||
| $222K-1.3% | $225K-80.0% | $1.12M+8,538% | $13K-98.2% | $718K+5,423% | ||
| —— | $0— | $0— | $0-100% | $11K-64.5% | ||
| $222K-21.8% | $284K-82.6% | $1.63M-98.5% | $110.4M+1,168% | $8.71M-83.1% | ||
| $498K+101% | -$37.96M+36.9% | -$60.19M-162% | $97.68M+763% | -$14.72M-182% | ||
| $431K-23.3% | $562K+88.6% | $298K-22.2% | $383K-3.0% | $395K+33.0% | ||
| $2.84M— | —— | $30K-97.0% | $1M+65.5% | $605K— | ||
| $105K-1.9% | $107K-0.9% | $108K-1.8% | $110K-1.8% | $112K-43.4% | ||
| —— | $6.5K0.0% | $6.5K0.0% | $6.5K0.0% | $6.5K— | ||
| $25.55M+7.4% | $23.79M+15.0% | $20.68M+42.6% | $14.5M-17.6% | $17.6M-17.5% | ||
| —— | $0— | $0— | $0-100% | $11K-64.5% | ||
| —— | $0-100% | $219K-40.5% | $368K+65.8% | $222K— | ||
| —— | $27.04M0.0% | $27.04M0.0% | $27.04M0.0% | $27.04M+130% | ||
| —— | —— | —— | $2.54M-69.1% | $8.22M— | ||
| —— | —— | —— | —— | —— | ||
| -$16.79M-120% | -$7.63M+29.9% | -$10.89M— | —— | —— | ||
| -$16.79M-120% | -$7.63M+29.9% | -$10.89M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Trevi Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.